Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20597255 | 1.00 | MDM2 (0.43) | MDM2MDM4TP53TACR1PTPN1 | |
| SCHEMBL13928511 | 0.89 | MDM2 (0.47) | MDM2MDM4TP53PTPN1KMT2A | |
| SCHEMBL233300 | 0.89 | MDM2 (0.47) | MDM2MDM4TP53PTPN1KMT2A | |
| SCHEMBL30431821 | 0.86 | MDM2 (0.49) | MDM2MDM4TP53PTPN1TAS1R3 | |
| SCHEMBL38666359 | 0.85 | MDM2 (0.53) | MDM2MDM4TP53TAS1R3TAS1R1 | |
| SCHEMBL22444667 | 0.84 | MDM2 (0.53) | MDM2MDM4TP53PTPN1 | |
| SCHEMBL2251221 | 0.83 | MDM2 (0.46) | MDM2MDM4TP53PTPN1KMT2A | |
| SCHEMBL20763341 | 0.83 | PTPN1 (0.34) | MDM2MDM4TP53PTPN1 | |
| SCHEMBL29633816 | 0.82 | MDM4 (0.45) | MDM2MDM4TP53PTPN1 | |
| SCHEMBL25259834 | 0.82 | MDM2 (0.53) | MDM2MDM4TP53PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055223-A1 | TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-21 | — | — | US | disclosed |
| US-20190055223-A1 | TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-21 | — | — | US | disclosed |
| EP-3421463-A1 | NEW TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017144015-A1 | NEW TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF | 江苏恒瑞医药股份有限公司 | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055223-A1 | TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF | VIP, HABP2, FURIN | MDM2 4629/4885MDM4 4633/4885TP53 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.